-

SpineX Inc. and VIVATRONIX Tech Pvt. Ltd. Announce CDSCO Approval of xStep Device for the Treatment of Paralysis in India

FREMONT, Calif. & BANGALORE, India--(BUSINESS WIRE)--VIVATRONIX Tech Pvt. Ltd. (Bangalore, India) and SpineX Inc. (Fremont, CA, USA) proudly announce that the Central Drugs Standard Control Organization (CDSCO), India’s national regulatory authority, has approved xStep (powered by SpineX) for clinical and home use in India.

Empowering Independence. Restoring Confidence. Lets xStep Forward!!

Share

The xStep device delivers painless, noninvasive electrical stimulation to the spinal cord—without the need for surgery—to help restore motor function, mobility, and independence in individuals living with paralysis.

Formerly known as SCiP™ or SCONE™, the xStep technology has been recognized by the U.S. Food and Drug Administration (FDA) as a Breakthrough Device for two distinct indications. It has demonstrated promising results in multiple global clinical trials, and SpineX continues to collaborate on investigator-initiated studies validating the safety, efficacy, and transformative potential of noninvasive spinal neuromodulation therapy.

“xStep’s CDSCO approval represents a breakthrough for neurorehabilitation—bringing world-class, life-changing therapy within reach for patients in India and beyond,” said Dr. Sachin Kandhari, MD, a leading Key Opinion Leader in neuromodulation and neurorehabilitation.

“This is a defining moment for us. With CDSCO approval, patients who have long been waiting for hope and recovery now have access to proven, noninvasive therapy. It’s no longer a question of if—it’s about making it happen now,” said Dr. Parag Gad, PhD, CEO of SpineX Inc. and VIVATRONIX Tech Pvt. Ltd.

With CDSCO approval, SpineX Inc. and VIVATRONIX Tech Pvt. Ltd. are poised to expand access to advanced neurorehabilitation technology in India and worldwide—marking a major step toward transforming the standard of care for individuals living with paralysis.

About SpineX Inc.

SpineX Inc., headquartered in Fremont, California, is a clinical-stage neuromodulation company developing noninvasive spinal cord stimulation technologies aimed at restoring mobility and function for individuals living with neurological disorders such as paralysis and cerebral palsy.

About VIVATRONIX Tech Pvt. Ltd.

VIVATRONIX Tech Pvt. Ltd., based in Bangalore, India, is dedicated to bringing cutting-edge neurotechnology and rehabilitation solutions to patients across India and emerging markets through collaboration, innovation, and patient-centered care.

More News From SpineX Inc.

SpineX Inc. Announces Significant Improvement in Urinary Bladder Function in Paralyzed Individuals with SCONE™ Therapy

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc., a pioneering medical technology company developing innovative non-surgical spinal cord neuromodulation solutions, today announced the results of its global, multisite pivotal trial, CONTINENCE, evaluating the safety and efficacy of SCONE™ therapy for neurogenic bladder (NB) in individuals with paralysis due to spinal cord injury (SCI), stroke, or multiple sclerosis (MS). The study demonstrated a statistically significant improvement in NB symptoms in t...

SpineX Closes Recruitment for SCONE™ Clinical Trial

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device. The clinical trial—Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study— began in May 2022. SCONE is an innovative device that treats urinary incontinence allowing people living with neurogenic bladder due to spinal cord injury, multiple sclerosis, or stroke to live life on their own terms. SpineX scientists and resea...

SpineX Announces Successful in-Human Results to Treat Adults with Cerebral Palsy

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. today announced groundbreaking results in its first in-human study treating an adult with Cerebral Palsy (CP). The study, published in the esteemed medical journal BioElectronic Medicine, demonstrates significant functional improvements in an adult with CP after treatment with the company’s proprietary non-surgical SCiP™ therapy. Led by Drs. Rahul Sachdeva, PhD and Kristin Girshin, PT, DPT, this study affirms how after just eight weeks of SCiP therapy t...
Back to Newsroom